Preparation and stability of lipid-coated nanocapsules of cisplatin: Anionic phospholipid specificity

Biochimica et Biophysica Acta - Biomembranes

Volumn 1663, Issue 1-2, 2004, Pages 135-142

  Velinova, Maria J ^a   Staffhorst, Rutger W H M ^a   Mulder, Willem J M ^a   Dries, Arno S ^a   Jansen, Bart A J ^a   De Kruijff, Ben ^a   De Kroon, Anton I P M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anionic phospholipid; Cisplatin; Drug delivery; Lipid formulation; Nanocapsule; Stability

Indexed keywords

ANION; CHOLESTEROL; CISPLATIN; LIPID; MACROGOL 2000; NANOCAPSULE; PHOSPHATIDIC ACID; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHOLIPID; WATER;

ARTICLE; CYTOTOXICITY; DRUG FORMULATION; DRUG SPECIFICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID COMPOSITION; MATERIAL COATING; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PARTICLE RESUSPENSION; PRIORITY JOURNAL; SERUM; TEMPERATURE;

ANIMALS; ANIONS; ANTINEOPLASTIC AGENTS; CAPSULES; CELL LINE, TUMOR; CISPLATIN; DRUG COMPOUNDING; DRUG STABILITY; FREEZING; HUMANS; MICE; NANOTECHNOLOGY; PHOSPHOLIPIDS; TEMPERATURE; WATER;

EID: 2442423519     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2004.03.002     Document Type: Article

References (34)

1. Rosencweig M., von Hoff D.D., Slavik M., Muggia F.M. Cis- diamminedichloroplatinum (II). A new anticancer drug. Ann. Intern. Med. 86:1977;803-812
2. Loehrer P.J., Einhorn L.H. Drugs five years later. Cisplatin. Ann. Intern. Med. 100:1984;704-713
3. Lippert B. Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. 1999;Wiley-VCH, New York
4. Cohen S.M., Lippard S.J. Cisplatin: from DNA damage to cancer chemotherapy. Prog. Nucleic Acid Res. Mol. Biol. 67:2001;93-130
5. Hill J.M., Speer R.J. Organo-platinum complexes as antitumor agents. (review) Anticancer Res. 2:1982;173-186
6. Calvert H., Judson I., van der Vijgh W.J. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv. 17:1993;189-217
7. Giaccone G. Clinical perspectives on platinum resistance. Drugs. 59(Suppl. 4):2000;9-17
8. Long D.F., Repta A.J. Cisplatin: chemistry, distribution and biotransformation. Biopharm. Drug Dispos. 2:1981;1-16
9. Reszka R., Fichtner I., Nissen E., Arndt D., Ladhoff A.M. Preparation, characterization, therapeutic efficacy and toxicity of liposomes, containing the anti-tumour drug cis-dichlorodiamineplatinum(II). J. Microencapsul. 4:1987;201-212
10. Steerenberg P.A., Storm G., de Groot G., Bergers J.J., Claessen A., de Jong W.H. Liposomes as a drug carrier system for cis- diamminedichloroplatinum(II): I. Binding capacity, stability and tumor cell growth inhibition in vitro. Int. J. Pharm. 40:1987;51-62
11. Gondal J.A., Preuss H.G., Swartz R., Rahman A. Comparative pharmacological, toxicological and antitumoral evaluation of free and liposome-encapsulated cisplatin in rodents. Eur. J. Cancer. 29A:1993;1536-1542
12. Newman M.S., Colbern G.T., Working P.K., Engbers C., Amantea M.A. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother. Pharmacol. 43:1999;1-7
13. Peleg-Shulman T., Gibson D., Cohen R., Abra R., Barenholz Y. Characterization of sterically stabilized cisplatin liposomes by nuclear magnetic resonance. Biochim. Biophys. Acta. 1510:2001;278-291
14. Vaage J., Donovan D., Wipff E., Abra R., Colbern G., Uster P., Working P. Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int. J. Cancer. 80:1999;134-137
15. Harrington K.J., Lewanski C.R., Northcote A.D., Whittaker J., Wellbank H., Vile R.G., Peters A.M., Stewart J.S. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann. Oncol. 12:2001;493-496
16. Kim E.S., Lu C., Khuri F.R., Tonda M., Glisson B.S., Liu D., Jung M., Hong W.K., Herbst R.S. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer. 34:2001;427-432
17. Meerum Terwogt J.M., Groenewegen G., Pluim D., Maliepaard M., Tibben M.M., Huisman A., ten Bokkel Huinink W.W., Schot M., Welbank H., Voest E.E., Beijnen J.H., Schellens J.M. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Cancer Chemother. Pharmacol. 49:2002;201-210
18. Burger K.N.J., Staffhorst R.W.H.M., de Vijlder H.C., Velinova M.J., Bomans P.H., Frederik P.M., de Kruijff B. Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity. Nat. Med. 8:2002;81-84
19. Allen T.M., Hansen C., Martin F., Redemann C., Yau-Yong A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta. 1066:1991;29-36
20. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Mathhay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U. S. A. 88:1991;11460-11464
21. Bremer A., Häner M., Aebi U. Celis J.E. Negative Staining in Cell Biology. A Laboratory Handbook. vol. 3:1998;277-284 Academic Press, San Diego
22. Bénard J., da Silva J., de Blois M.C., Boyer P., Duvillard P., Chiric E., Riou G. Characterization of a human ovarian adenocarcinoma line, IGROV 1, in tissue culture and in nude mice. Cancer Res. 45:1985;4970-4979
23. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112
24. Burger K.N.J., Staffhorst R.W.H.M., de Kruijff B. Interaction of the anti-cancer drug cisplatin with phosphatidylserine in intact and semi-intact cells. Biochim. Biophys. Acta. 1419:1999;43-54
25. Rouser G., Fleischer S., Yamamoto A. Two-dimensional thin-layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 5:1970;494-496
26. Speelmans G., Staffhorst R.W.H.M., Versluis K., Reedijk J., de Kruijff B. Cisplatin complexes with phosphatidylserine in membranes. Biochemistry. 36:1997;10545-10550
27. Demel R.A., Kinsky S.C., Kinsky C.B., van Deenen L.L.M. Effects of temperature and cholesterol on the glucose permeability of liposomes prepared with natural and synthetic lecithins. Biochim. Biophys. Acta. 150:1968;655-665
28. Fettiplace R., Haydon D.A. Water permeability of lipid membranes. Physiol. Rev. 60:1980;510-550
29. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51:1999;691-743
30. Sankaram M.B., Thompson T.E. Interaction of cholesterol with various glycerophospholipids and sphingomyelin. Biochemistry. 29:1990;10670-10675
31. Speelmans G., Sips W.H.H.M., Grisel R.J.H., Staffhorst R.W.H.M., Fichtinger-Schepman A.M.J., Reedijk J., de Kruijff B. The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride concentration. Biochim. Biophys. Acta. 1283:1996;60-66
32. Spanjer H.H., van Galen M., Roerdink F.H., Regts J., Scherphof G.L. Intrahepatic distribution of small unilamellar liposomes as a function of liposomal lipid composition. Biochim. Biophys. Acta. 863:1986;224-230
33. Klibanov A.L., Maruyama K., Beckerleg A.M., Torchilin V.P., Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta. 1062:1991;142-148
34. Chiu G.N.C., Bally M.B., Mayer L.D. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim. Biophys. Acta. 1510:2001;56-69